Format

Send to

Choose Destination
Oncogene. 2013 Jul 4;32(27):3306-10. doi: 10.1038/onc.2012.372. Epub 2012 Aug 27.

miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling.

Author information

1
Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria. christoph.gebeshuber@meduniwien.ac.at

Abstract

Dysregulation of micro RNAs is crucially implicated in tumorigenesis. We detected downregulation of miR-100 in breast cancer cells, leading to an upregulation of the proliferation- and survival-promoting oncogene insulin-like growth factor (IGF) 2. Stable overexpression of miR-100 strongly reduced IGF2 expression and inhibited tumor growth. In invasive human breast tumors, miR-100 was reduced about fourfold as compared with benign patient samples, whereas IGF2 was strongly enhanced. MiR-100 has also been shown to suppress other proteins of the IGF/mammalian target of rapamycin (mTOR) signaling cascade in different human tumors. Our results reveal miR-100 as a context-dependent master regulator of the IGF/mTOR pathway and a potential target for therapeutic approaches.

PMID:
22926517
DOI:
10.1038/onc.2012.372
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center